Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: Experiences and subgroup analysis in a cohort with frequent methotrexate use

Mikhail M. Kostik, Ekaterina V. Gaidar, Alla Y. Hynnes, Margarita F. Dubko, Vera V. Masalova, Ludmila S. Snegireva, Irina A. Chikova, Eugenia A. Isupova, Tatiana N. Nikitina, Elena D. Serogodskaya, Olga V. Kalashnikova, Angelo Ravelli, Vyacheslav G. Chasnyk

Research output: Contribution to journalArticle

Abstract

Objective To evaluate the ability of methotrexate (MTX) to prevent the onset of uveitis in Russian children with juvenile idiopathic arthritis (JIA). Methods The clinical charts for all consecutive patients who received a stable management for at least 2 years with or without MTX were reviewed. Patients who were given systemic medications other than MTX (except NSAID) and patients with systemic arthritis, rheumatoid factor-positive arthritis, or enthesitis-related arthritis were excluded. Each patient was examined after at least a 2-year follow-up period after the first visit to establish whether uveitis had occurred. Results A total of 281 patients with a median disease duration of 3.8 years were included. 191 patients (68%) were treated with MTX. During the observation period, 64 patients (22.8%) developed uveitis, a median of 1.6 year after disease onset. The frequency of uveitis was lower in MTX-treated than in MTX-untreated patients (11.5% vs. 46.7%, respectively, OR=6.7 (95%CI:3.7-12.3), p=0.0000001). Survival analysis confirmed that patients treated with MTX had a lower probability of developing uveitis (HR=4.35, p=0.000001). In subgroup analysis it was shown that MTX was more preventive in boys than in girls, and in patients with JIA onset age of over 5 years compared to those with disease onset less than 5 years. The data of survival analysis of MTX prevention has shown that benefits do not depend on the number of active joints and ANA status. Conclusion Our study corroborates a previous observation that MTX therapy may prevent the onset of uveitis in children with JIA. Randomised controlled trials are required to confirm our results.

Original languageEnglish
Pages (from-to)714-718
Number of pages5
JournalClinical and Experimental Rheumatology
Volume34
Issue number4
Publication statusPublished - 2016

Keywords

  • Juvenile idiopathic arthritis
  • Methotrexate
  • Uveitis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: Experiences and subgroup analysis in a cohort with frequent methotrexate use'. Together they form a unique fingerprint.

  • Cite this

    Kostik, M. M., Gaidar, E. V., Hynnes, A. Y., Dubko, M. F., Masalova, V. V., Snegireva, L. S., Chikova, I. A., Isupova, E. A., Nikitina, T. N., Serogodskaya, E. D., Kalashnikova, O. V., Ravelli, A., & Chasnyk, V. G. (2016). Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: Experiences and subgroup analysis in a cohort with frequent methotrexate use. Clinical and Experimental Rheumatology, 34(4), 714-718.